Preclinical data showing that the MMR protein mutL homolog 1 (MLH1) can be re-expressed using DAC in ovarian and colon cancer cells to improve sensitivity to platinum agents spurred the development of several clinical trials [17–19]. The gene discussed is MLH1; the disease is colonic neoplasm.